JP2023531230A - 全身性硬化症の治療のための抗ｓ１００ａ４抗体 - Google Patents

全身性硬化症の治療のための抗ｓ１００ａ４抗体 Download PDF

Info

Publication number
JP2023531230A
JP2023531230A JP2022579129A JP2022579129A JP2023531230A JP 2023531230 A JP2023531230 A JP 2023531230A JP 2022579129 A JP2022579129 A JP 2022579129A JP 2022579129 A JP2022579129 A JP 2022579129A JP 2023531230 A JP2023531230 A JP 2023531230A
Authority
JP
Japan
Prior art keywords
antibody
seq
use according
amino acid
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531230A5 (https=
Inventor
クリンゲルホーフェル，ジョーグ
ハレン，ジョナス
フセイン，リズワン，イクバル
ディストラー，ジョーグ，ハンス，ウィルヘルム
トムシク，ミハル
バス，ティム
マッカン，ダラ
Original Assignee
アークス セラピューティクス エーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アークス セラピューティクス エーエス filed Critical アークス セラピューティクス エーエス
Publication of JP2023531230A publication Critical patent/JP2023531230A/ja
Publication of JP2023531230A5 publication Critical patent/JP2023531230A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022579129A 2020-06-30 2021-06-30 全身性硬化症の治療のための抗ｓ１００ａ４抗体 Pending JP2023531230A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20183251.6 2020-06-30
EP20183251 2020-06-30
US202163147485P 2021-02-09 2021-02-09
US63/147,485 2021-02-09
PCT/EP2021/068038 WO2022003042A1 (en) 2020-06-30 2021-06-30 Anti-s100a4 antibodies for the treatment of systemic sclerosis

Publications (2)

Publication Number Publication Date
JP2023531230A true JP2023531230A (ja) 2023-07-21
JP2023531230A5 JP2023531230A5 (https=) 2024-06-28

Family

ID=76601225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579129A Pending JP2023531230A (ja) 2020-06-30 2021-06-30 全身性硬化症の治療のための抗ｓ１００ａ４抗体

Country Status (7)

Country Link
US (1) US20230220058A1 (https=)
EP (1) EP4171752A1 (https=)
JP (1) JP2023531230A (https=)
CN (1) CN115867355A (https=)
AU (1) AU2021301244A1 (https=)
CA (1) CA3183062A1 (https=)
WO (1) WO2022003042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250011405A1 (en) * 2021-11-19 2025-01-09 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用
WO2025188905A1 (en) * 2024-03-08 2025-09-12 The Board Of Regents Of The University Of Texas System Anti-s100a antibodies and related compositions and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014068300A1 (en) * 2012-10-30 2014-05-08 Cancer Research Technology Limited Anti-s100a4 antibody molecules and their uses
JP2017101050A (ja) * 2010-06-14 2017-06-08 リケラ バイオメッド エスエーＬｙｋｅｒａ Ｂｉｏｍｅｄ Ｓａ Ｓ１００ａ４抗体およびその治療上の使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA3207703A1 (en) * 2021-02-09 2022-08-18 Jonas Hallen Anti-s100a4 humanized antibodies, uses and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017101050A (ja) * 2010-06-14 2017-06-08 リケラ バイオメッド エスエーＬｙｋｅｒａ Ｂｉｏｍｅｄ Ｓａ Ｓ１００ａ４抗体およびその治療上の使用
WO2014068300A1 (en) * 2012-10-30 2014-05-08 Cancer Research Technology Limited Anti-s100a4 antibody molecules and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNALS OF THE RHEUMATIC DISEASES, vol. 74, JPN6025023817, 2014, pages 1748 - 1755, ISSN: 0005807252 *
NATURE REVIEWS RHEUMATOLOGY, vol. 10, JPN6025023816, 2014, pages 322, ISSN: 0005619321 *

Also Published As

Publication number Publication date
AU2021301244A1 (en) 2023-03-02
WO2022003042A1 (en) 2022-01-06
CN115867355A (zh) 2023-03-28
CA3183062A1 (en) 2022-01-06
EP4171752A1 (en) 2023-05-03
US20230220058A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
US10918737B2 (en) Methods and pharmaceutical composition for the treatment of cancer
IL269081B1 (en) Fc-optimal anti-CD25 for specific cell depletion of the
AU2018266784C1 (en) LRRC33 inhibitors and use thereof
JP2023531230A (ja) 全身性硬化症の治療のための抗ｓ１００ａ４抗体
JP2022512642A (ja) がんを治療するための抗ＭｅｒＴＫ抗体
CN113271964A (zh) 化脓性汗腺炎治疗中使用的抗cd40抗体
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
US20220331425A1 (en) Treatment of cancers with gm-csf antagonists
KR20250005246A (ko) 항-cd19 작용제에 대한 투여 요법 및 이의 용도
NL2021591B1 (en) MuSK activation
US20240043562A1 (en) Musk activation
CA3099260C (en) Lrrc33 inhibitors and use thereof
HK40103766A (en) Lrrc33 inhibitors and use thereof
AU2024277733A1 (en) Methods of treating cancer with anti-mica/b antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303